Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 12/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CALML3 | P27482 | 5/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24923221 | 0.85 | CALML3 (0.68) | MAOACYP3A4CYP2C19CALML3MAOB | |
| SCHEMBL28748378 | 0.82 | MAOA (0.49) | MAOACYP3A4CYP2C19CALML3MAOB | |
| SCHEMBL27573562 | 0.80 | CYP2C19 (0.51) | MAOACYP3A4CYP2C19CALML3MAOB | |
| SCHEMBL27573559 | 0.80 | CYP2C19 (0.51) | MAOACYP3A4CYP2C19CALML3MAOB | |
| SCHEMBL3093368 | 0.79 | MAOA (0.56) | MAOACYP3A4CYP2C19CALML3MAOB | |
| SCHEMBL27592144 | 0.79 | CALML3 (0.51) | MAOACYP3A4CYP2C19CALML3MAOB | |
| SCHEMBL27592147 | 0.79 | CALML3 (0.51) | MAOACYP3A4CYP2C19CALML3MAOB | |
| SCHEMBL23501094 | 0.78 | MAOA (0.77) | MAOACYP3A4CYP2C19CALML3MAOB | |
| SCHEMBL29932263 | 0.78 | MAOA (0.77) | MAOACYP3A4CYP2C19CALML3MAOB | |
| SCHEMBL23500432 | 0.78 | MAOA (0.77) | MAOACYP3A4CYP2C19CALML3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566023-B2 | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof | AKAGERA MEDICINES, INC. (US) | 2023-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566023-B2 | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof | OXA1L, THPO, TBCD | MAOA 1751/4885CYP3A4 773/4885CYP2C19 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.